Omics in Cutaneous Melanoma.

The advancement of multidimensional omics technologies holds immense promise for the future of medical treatment, particularly in addressing a wide range of human illnesses. Melanoma, which ranks among the most aggressive malignant pathologies affecting the skin, is a complex and heterogeneous oncological condition. There exist mutations that are tightly intertwined with the biological behavior of tumors, significantly influencing the course and outcome of the disease. Specifically, a subset of these mutations has been identified as mutually exclusive, involving specific signaling molecules and signaling cascades. Simultaneously, it has now been well established that inactivation of one component can activate alternative signaling pathways, ultimately leading to a more pronounced intensification of carcinogenesis. Consequently, this study not only reveals the impact of transcription factors and growth factors on carcinogenesis, but also emphasizes the importance of non-coding RNA (microRNAs), which constitute a unique set of biomarkers that determine the biological and molecular characteristics of tumors. It is important to note that genomic, transcriptomic, and proteomic profiling of tumors do not provide a complete assessment of their invasive and metastatic potential. The article provides contemporary insights into multimodal approaches for identifying molecular subtypes of melanoma.